Dr Alison Winger has been appointed General Manager of Novozyme Ireland.
In addition to this role, she will remain as global head of product development at Novozymes within OneHealth’s Human Health division. She leads a global team of scientists developing new and innovative products including Novozymes’ proprietary enzymes, probiotics, prebiotics and vitamins.
In this role, Cork-based Dr Winger leads the Novozymes division in Ireland, Denmark and the US, working closely with the commercial community to create branded products.
She will take over the role as general manager of Novozymes Ireland from leading gut health scientist Dr Barry Kiley, who recently retired after a distinguished career in precision biotics.
Commenting on his appointment, Mr Winger said: “I am delighted to be furthering my career at Novozymes Ireland by taking on this role. Barry Keeley has made a huge contribution to science in Cork and Ireland. , has made a significant contribution to science in Cork and Ireland: precision biotics.
“Novozymes Ireland is a great place to work, the technology we use is truly amazing and we continue to discover new solutions. We are a company with science and innovation at our core. Everything we do starts with our unique 1 in a trillion philosophy: helping people support their microbiome and take control of their health.
“I am very much looking forward to the exciting challenges that lie ahead in my new role as General Manager in 2024.”
Ms Winger is originally from New Zealand and held several academic research positions around the world before moving to Ireland in 2014. Since coming here, she has worked for a number of biotech and pharmaceutical companies, including Monaghan Biosciences Ltd, LEO Pharma, and Deerland Probiotics and Enzymes, before joining Novozymes Ireland in 2021.
She is the author of several publications, including three enzyme patents and nine peer-reviewed papers in the field of enzymes and probiotics.
PrecisionBiotics began more than 20 years ago when scientists began studying thousands of bacterial cultures with experts at the APC Microbiome Institute at UCC, Ireland, one of the world’s leading microbiome research centres. Ta.
Since then, the team has discovered hundreds of different bacterial cultures and conducted rigorous scientific tests on each one. Among these hundreds, there are a few special probiotic bacteria that stand out because of their precise and significant positive impact on human intestinal health.
Once these probiotics pass all clinical trials and testing in Ireland, the UK and Europe, the PrecisionBiotics team will create high quality, convenient products containing these solutions for consumers and clinicians.